iReact - Intelligent Multimodal Digital Ophthalmic Measuring Device with enabled AI Tele-Ophthalmology

iReact - 具有人工智能远程眼科功能的智能多模态数字眼科测量设备

• 批准号: 10031483
• 金额: $ 44.42万
• 依托单位: VIVO SMART MEDICAL DEVICES LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10031483
• 关键词: iReact; Intelligent; Multimodal; Digital; Ophthalmic

This UK/Singapore R&D collaboration combines a team of specialist Medical Device Designers, Human-factors, Software/Electronic Engineers, Eye Specialist clinicians to develop an affordable, patented, reliable, and easy-to-use device, the iReact Intelligent Multimodal Digital Ophthalmic Measuring Device with enabled AI Tele-Ophthalmology.Eye tests are a ubiquitous part of modern healthcare. Preservation of sight and the early detection of both eye and other diseases are accomplished by a range of well described tests.False-positive referrals, existing waiting-lists, Covid-exacerbation and ageing populations requiring long-term eye-care is growing without the commensurate number of Ophthalmologists and Clinical resources to meet this demand-pressure on capacity - increasing risk of adverse-outcomes-for-patients.This creates the need for an innovative ophthalmic-technology to reduce-demand and rapidly identify and monitor eye-disease in patients who need it most.iReact technology combines eye imaging assessment and testing bringing it to millions of patients in the UK, Singapore and Global market. Apart from the obvious health and reduction in disability benefits this technology will also bring significant cost savings to health and social care services. The market, and return on investments, is worldwide.Measurements currently only made in specialist eye clinics, will be eventually be available through high street opticians and Primary Care using a sophisticated but simple to operate device.Reducing eye-care outpatient appointments with the iReact, deployed at scale, will save the NHS £millions/year by reducing unnecessary referrals and enabling community/primary care-eye-testing.Ophthalmology is one of the busiest specialties in the NHS, providing over 9 million outpatient appointments per year costing over £1Billion/year.Age-related sight-impairing diseases such as Glaucoma have dramatically increased in prevalence and in treatment costs as the population ages. However, a significant proportion of sight-loss and blindness is preventable if diagnosed early and with careful monitoring. Unchecked, sight-loss and blindness cause a considerable health burden on individuals and the state. Its estimated sight-loss in adults costs the UK economy £28 billion a year.The NHS Long Term plan recognises these demands and supports the need for eye-care services at Community and Primary care that can help reduce unnecessary referrals to specialist eye clinics. Provided at scale, linked via Integrated-Eye-Care-Pathways focusing on early detection, effective referrals and prompt access and treatment helping to reduce unnecessary sight-loss.

这项英国/新加坡的研发合作结合了专业医疗设备设计师，人为因素，软件/电子工程师，眼科专家临床医生的团队，开发了一种负担得起的，专利的，可靠的，易于使用的设备，iReact智能多模态数字眼科测量设备，启用人工智能远程眼科。保护视力和早期发现眼睛和其他疾病是通过一系列描述良好的测试来完成的。假阳性转诊，现有的等待名单，需要长期眼部护理的新冠肺炎加重和老龄化人群正在增长，但没有相应数量的眼科医生和临床资源来满足这一需求-对能力的压力-增加了不良结局的风险-这就需要一种创新的眼科技术，以减少需求，并快速识别和监测最需要的患者的眼部疾病。iReact技术结合了眼部成像评估和测试，使其成为英国，新加坡和全球市场的数百万患者。除了明显的健康和减少残疾福利外，这项技术还将为卫生和社会保健服务节省大量费用。市场和投资回报是全球性的。目前仅在专科眼科诊所进行的测量，最终将通过商业街眼镜商和初级保健使用复杂但操作简单的设备提供。减少与iReact的眼科门诊预约，大规模部署，将通过减少不必要的转诊和使社区/初级保健-眼-眼科是NHS中最繁忙的专科之一，每年提供超过900万个门诊预约，花费超过10亿英镑/年。随着人口老龄化，与眼科相关的视力损害疾病如青光眼的患病率和治疗费用急剧增加。然而，如果及早诊断并进行仔细监测，很大一部分视力丧失和失明是可以预防的。如果不加以控制，失明和失明会给个人和国家造成相当大的健康负担。据估计，成年人视力丧失每年给英国经济造成280亿英镑的损失。NHS长期计划认识到这些需求，并支持社区和初级保健对眼科护理服务的需求，这有助于减少不必要的眼科专科诊所转诊。大规模提供，通过综合眼科护理途径相联系，重点是早期发现，有效转诊，及时获得和治疗，有助于减少不必要的视力丧失。